MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526453 | Name: Tibric acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tibric acid is a hepatic peroxisome proliferator.

Chemical Structure

Tibric acid
Tibric acid
CAS#37087-94-8

Theoretical Analysis

MedKoo Cat#: 526453

Name: Tibric acid

CAS#: 37087-94-8

Chemical Formula: C14H18ClNO4S

Exact Mass: 331.0645

Molecular Weight: 331.81

Elemental Analysis: C, 50.68; H, 5.47; Cl, 10.68; N, 4.22; O, 19.29; S, 9.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tibric acid
IUPAC/Chemical Name
Benzoic acid, 2-chloro-5-((3,5-dimethyl-1-piperidinyl)sulfonyl)-, (cis)-
InChi Key
IFXSWTIWFGIXQO-AOOOYVTPSA-N
InChi Code
InChI=1S/C14H18ClNO4S/c1-9-5-10(2)8-16(7-9)21(19,20)11-3-4-13(15)12(6-11)14(17)18/h3-4,6,9-10H,5,7-8H2,1-2H3,(H,17,18)/t9-,10+
SMILES Code
O=C(O)C1=CC(S(=O)(N2C[C@H](C)C[C@H](C)C2)=O)=CC=C1Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 331.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu RC, Hahn C, Hurtt ME. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam Appl Toxicol. 1996 Mar;30(1):102-8. PubMed PMID: 8812244. 2: Morgan C, Bronfman M. Saturable binding sites for the coenzyme A ester of nafenopin, a peroxisome proliferator, in rat liver cytosol. Xenobiotica. 1995 Dec;25(12):1293-300. PubMed PMID: 8719905. 3: Bronfman M, Orellana A, Morales MN, Bieri F, Waechter F, Stäubli W, Bentley P. Potentiation of diacylglycerol-activated protein kinase C by acyl-coenzyme A thioesters of hypolipidaemic drugs. Biochem Biophys Res Commun. 1989 Mar 31;159(3):1026-31. PubMed PMID: 2930549. 4: Moody DE, Reddy JK, Azarnoff DL. Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents. Biochem Pharmacol. 1984 Aug 15;33(16):2591-7. PubMed PMID: 6431985. 5: Parthasarathy S, Kritchevsky D, Baumann WJ. Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis. Proc Natl Acad Sci U S A. 1982 Nov;79(22):6890-3. PubMed PMID: 6294663; PubMed Central PMCID: PMC347239. 6: Oller WL, Kendall DC, Bowman MC. Determination of tibric acid and clofibrate in animal feed, wastewater and hunan urine. J Anal Toxicol. 1982 Jul-Aug;6(4):175-80. PubMed PMID: 6811800. 7: Orton TC, Parker GL. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metab Dispos. 1982 Mar-Apr;10(2):110-5. PubMed PMID: 6124394. 8: Reddy MK, Hollenberg PF, Reddy JK. Partial purification and immunoreactivity of an 80 000-molecular-weight polypeptide associated with peroxisome proliferation in rat liver. Biochem J. 1980 Jun 15;188(3):731-40. PubMed PMID: 6781475; PubMed Central PMCID: PMC1161955. 9: De Rosa L, Giangrandi E, Murante N, Scaroina F. [Treatment of hyperlipemia with tibric acid (TA)]. Minerva Med. 1978 Jun 2;69(28):1917-22. Italian. PubMed PMID: 208024. 10: Smith FR, Noble RP, Goodman DS. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound. Atherosclerosis. 1978 Mar;29(3):345-54. PubMed PMID: 666884. 11: Moody DE, Reddy JK. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes. Am J Pathol. 1978 Feb;90(2):435-46. PubMed PMID: 623209; PubMed Central PMCID: PMC2018144. 12: Lazarow PB. Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat. Science. 1977 Aug 5;197(4303):580-1. PubMed PMID: 195342. 13: Cayen MN, Dubuc J, Dvornik D. Effect of tibric acid on hepatic cholesterol synthesis in rats. Lipids. 1977 Aug;12(8):684-8. PubMed PMID: 895418. 14: Bielmann P, Brun D, Moorjani S, Gagnon MA, Tétreault L, Lupien PJ. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia. Int J Clin Pharmacol Biopharm. 1977 Apr;15(4):166-71. PubMed PMID: 192685. 15: Miettinen TA. Treatment of hyperlipoproteinemias with neomycin, probucol and tibric acid. Adv Exp Med Biol. 1977;82:483-8. PubMed PMID: 920404. 16: Lisch HJ, Sailer S, Braunsteiner H. [Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia]. Arzneimittelforschung. 1977;27(10):2017-20. German. PubMed PMID: 579116. 17: Beaumont JL, Dachet C. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters: its significance for the mechanism of lipid lowering by clofibrate and related drugs. Atherosclerosis. 1976 Nov-Dec;25(2-3):255-66. PubMed PMID: 188431. 18: Carmena R, González R Florez J, Sanchis J. [Treatment of hyperlipidemia with a new drug, tibric acid]. Rev Clin Esp. 1976 Jul 31;142(2):151-5. Spanish. PubMed PMID: 788065. 19: Beaumont JL, Dachet C. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters. Proc R Soc Med. 1976;69 Suppl 2:41-3. PubMed PMID: 1019153; PubMed Central PMCID: PMC1864029. 20: Kritchevsky D, Tepper SA, Story JA. Influence of four agents (tibric acid, DH 990, oxandrolone and Sch 9122) on aspects of lipid metabolism in rats). Arzneimittelforschung. 1976;26(5):862-4. PubMed PMID: 989359.